Stem Cell Clinic

Autologous Stem Cell Based Therapies Market: COVID 19 After Effect Shows an Increase in Revenue of Key Players Regeneus, Mesoblast, Pluristem…

By Stell Cell Research

Autologous Stem Cell Based Therapies Market has witnessed continuous growth within the past few years and is projected to grow even more throughout the forecast period (2020 2027). The analysis presents a whole assessment of the market and contains Future trends, Current Growth Factors, attentive opinions, facts, historical information, and statistically supported and trade valid market information.

The report, titled Global Autologous Stem Cell Based Therapies Market defines and briefs readers about its products, applications, and specifications. The research lists key companies operating in the global market and also highlights the key changing trends adopted by the companies to maintain their dominance. By using SWOT analysis and Porters five force analysis tools, the strengths, weaknesses, opportunities, and threats of key companies are all mentioned in the report. All leading players in this global market are profiled with details such as product types, business overview, sales, manufacturing base, competitors, applications, and specifications.

You Can Request A Demo Version of Report Before Buying (Higher Preference For Corporate Email ID User): https://www.worldwidemarketreports.com/sample/216517

Regeneus, Mesoblast, Pluristem Therapeutics Inc, U.S. STEM CELL Inc., Brainstorm Cell Therapeutics, Tigenix, Med cell Europe of the major organizations dominating the global market.(*Note: Other Players Can be Added per Request)

1. Industry outlookThis is where youll find the current state of the Autologous Stem Cell Based Therapies industry overall and where its headed. Relevant industry metrics like size, trends, life cycle, and projected growth included here. This report comes prepared with the data to back up your business idea. On a regional basis, the Global Autologous Stem Cell Based Therapies market has been segmented into Asia-Pacific, North America, Europe, Latin America, and the Middle East and Africa.

2. Target marketThis target market section of study includes the following:

User persona and characteristics: It includes demographics such as age, income, and location. It lets you know what their interests and buying habits are, as well as explain the best position to meet their needs.

Market size: How big is the potential Autologous Stem Cell Based Therapies market for your business? It brings to light the consumption in the Autologous Stem Cell Based Therapies industry by the type and application.

3. Competitive analysisDiscover your competitors. The report lets you know what youre up against, but it also lets you spot the competitions weaknesses. Are there customers that are underserved? What can you offer that similar businesses arent offering? The competitive analysis contains the following components:

Direct competitors: What other companies are offering similar products and services? Which companies are your true competitors?

Competitor strengths and weaknesses: What is your competition good at? Where do they fall behind? Get insights to spot opportunities to excel where others are falling short.

Barriers to entry: What are the potential pitfalls of entering the Autologous Stem Cell Based Therapies market? Whats the cost of entry? Is it prohibitively high, or easy to enter?

The window of opportunity:Does your entry into the Autologous Stem Cell Based Therapies industry rely on time-sensitive technology? Do you need to enter early to take advantage of an emerging market?

4. ProjectionsLikewise, We offered thoughtful, not hockey-stick forecasting.

Market share:We have given the consumption behavior of users. When you know how much can your future customers spend, then only youll understand how much of the Autologous Stem Cell Based Therapies industry you have a chance to grab, and here we came up with real stats and numbers.

Impact Analysis of COVID-19:The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into account the political, economic, social, and technological parameters.

Finally, It is one report that hasnt shied away from taking a critical look at the current status and future outlook for the consumption/sales of these products, by the end users and applications. Not forgetting the market share control and growth rate of the Autologous Stem Cell Based Therapies Industry, per application. Most noteworthy, this market analysis will help you find market blind spots.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends.

Contact Us:

Mr. ShahWorldwide Market ReportsSeattle, WA 98154,U.S.Email: [emailprotected]

Follow this link:
Autologous Stem Cell Based Therapies Market: COVID 19 After Effect Shows an Increase in Revenue of Key Players Regeneus, Mesoblast, Pluristem...

Canine Arthritis Treatment Market Size, Share 2020 Supply-Demand, Industry Research and End User Analysis, Outlook 2025| Says MRE Reports – Jewish…

By Stem Cell Clinics

The Canine Arthritis Treatment Market is expected to exceed more than US$ 3.18 Billion by 2024 at a CAGR of 4.4% in the given forecast period.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Elanco (Eli Lilly and Company), Boehringer Ingelheim, Zoetis Inc., Vetoquinol S.A., Bayer AG, Aratana Therapeutics Inc., Norbrook Laboratories Limited, VetStem Biopharma, and Dechra Pharmaceuticals Plc, among others. Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.

The Canine Arthritis Treatment Market is segmented on the lines of its treatment type, route of administration, end users and regional. Basis of End-User is segmented into Veterinary Hospitals and Clinics, Retail Pharmacies, Drug Stores and E-commerce. Based on Treatment Type it covers Non-steroidal anti-inflammatory drugs, Opioids and Stem Cell Therapy. Based on route of administration it covers Oral and Injectable. The Canine Arthritis Treatment Market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geographic market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.

Browse Full Report: https://www.marketresearchengine.com/canine-arthritis-treatment-market

Reasons to Buy this Report:

1) Obtain the most up to date information available on all Canine Arthritis Treatment Market.

2) Identify growth segments and opportunities in the industry.

3) Facilitate decision making on the basis of strong historic and forecast of Canine Arthritis Treatment Market.

4) Assess your competitors refining portfolio and its evolution.

Canine arthritis may be a chronic condition that ends up in inflammation of 1 or a lot of joints and progresses over time if left untreated. the foremost usually affected joints embody the knee, elbow, shoulder, hip and back. There are numerous causes of inflammatory disease in dogs like traumatic injuries, obesity, failure of correct bone development and lots of others. There are many sorts of canine arthritis however the foremost common is arthritis. It affects one in five adult dogs. The prevalence of arthritis will increase with the age of canines. Its a chronic disease characterised by the loss of gristle. It conjointly includes alternative abnormalities like osteophytotic in response to inflammation and pain.

The Canine Arthritis Treatment Market has been segmented as below:

By Treatment Type:

By Route of Administration:

By End-User:

This report provides:

1) An overview of the global market for Canine Arthritis Treatment Market and related technologies. 2) Analyses of global market trends, with data from 2015, estimates for 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2024. 3) Identifications of new market opportunities and targeted promotional plans for Canine Arthritis Treatment Market.

4) Discussion of research and development, and the demand for new products and new applications. 5) Comprehensive company profiles of major players in the industry.

Report Scope:

The scope of the report includes a detailed study of Canine Arthritis Treatment Market with the reasons given for variations in the growth of the industry in certain regions.

Request Sample Report from here: https://www.marketresearchengine.com/canine-arthritis-treatment-market

Table of Contents

4.1 Introduction

4.2 Drivers

4.3 Restrains

4.4 Industry Trends

4.5 Porters Five Forces Analysis

10.1 Elanco (Eli Lilly and Company)

10.2 Norbrook Laboratories Limited

10.3 Aratana Therapeutics Inc.

10.4 Dechra Pharmaceuticals Plc

10.5 VetStem Biopharma

10.6 Zoetis Inc.

10.7 Vetoquinol S.A.

10.8 Boehringer Ingelheim

10.9 Bayer AG

Other Related Market Research Reports:

Cardiac Assist Devices Market is Supposed to Reach at a CAGR of 10.02% by 2024

Cardiac Rehabilitation Devices Market is Supposed to Reach US$ 170 Billion by 2024

About MarketResearchEngine.com

Market Research Engine is a global market research and consulting organization. We provide market intelligence in emerging, niche technologies and markets. Our market analysis powered by rigorous methodology and quality metrics provide information and forecasts across emerging markets, emerging technologies and emerging business models. Our deep focus on industry verticals and country reports help our clients to identify opportunities and develop business strategies.

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

See the rest here:
Canine Arthritis Treatment Market Size, Share 2020 Supply-Demand, Industry Research and End User Analysis, Outlook 2025| Says MRE Reports - Jewish...

COVID-19 Analysis | Canine Stem Cell Therapy Market by Trends, Dynamic Innovation in Technology and 2026 Forecasts – 3rd Watch News

By Adult Stem Cells

Persistence Market Research (PMR) has published a new research report on canine stem cell therapy. The report has been titled, Canine Stem Cell Therapy Market: Global Industry Analysis 2016 and Forecast 20172026.Veterinary research has been used in regenerative and adult stem cell therapy andhas gained significant traction over the last decade.

Canine stem cell therapy products are identified to have gained prominence over the past five years, and according to the aforementioned research report, the market for canine stem cell therapy will expand at a moderate pace over the next few years.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/15550

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/15550

Though all animal stem cells are not approved by FDA, veterinary stem-cell manufacturers and university researchers have been adopting various strategies in order to meet regulatory approvals, and streamline and expedite the review-and-approval process. The vendors in the market are incessantly concentrating on research and development to come up with advanced therapy, in addition to acquiring patents.

In September 2017, VetStem Biopharma, Inc. received European patent granted to the University of Pittsburgh and VetStem received full license of the patent then. This patent will eventually provide the coverage for the ongoing commercial and product development programs of VetStem and might be also available for licensing to other companies who are rather interested in this field.

The other companies operating in the global market for canine stem cell therapy are VETherapy Corporation, Aratana Therapeutics, Inc., Regeneus Ltd, Magellan Stem Cells, Animal Cell Therapies, Inc., and Medrego, among others.

According to the Persistence Market Research report, the globalcanine stem cell therapy marketis expected to witness a CAGR of 4.2% during the forecast period 2017-2026. In 2017, the market was valued at US$ 151.4 Mn and is expected to rise to a valuation of US$ 218.2 Mn by the end of 2026.

Burgeoning Prevalence of Chronic Diseases in Dogs to Benefit Market

Adipose Stem Cells (ASCs) are the most prevalent and in-demand adult stem cells owing to their safety profile, ease of harvest, and use and the ability to distinguish into multiple cell lineages. Most early clinical research is focused on adipose stem cells to treat various chronic diseases such as arthritis, tendonitis, lameness, and atopic dermatitis in dogs.

A large area of focus in veterinary medicine is treatment of osteoarthritis in dogs, which becomes more prevalent with age. Globally, more than 20% dogs are suffering from arthritis, which is a common form of canine joint and musculoskeletal disease. Out of those 20%, merely 5% seem to receive the treatment.

However, elbow dysplasia in canine registered a prevalence rate of 64%, converting it into an alarming disease condition to be treated on priority. Thereby, with the growing chronic disorders in canine, the demand for stem cell therapy is increasing at a significant pace.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/15550

Expensive Nature of Therapy to Obstruct Growth Trajectory

Expensive nature and limited access to canine stem cell therapy has demonstrated to be a chief hindrance forestalling its widespread adoption. The average tier II and tier III veterinary hospitals lack the facilities and expertise to perform stem cell procedures, which necessitates the referral to a specialty vet hospital with expertise veterinarians.

A trained veterinary physician charges high treatment cost associated with stem cell therapy for dogs. Generally, dog owners have pet insurance that typically covers maximum cost associated with steam cell therapy to treat the initial injury but for the succeeding measures in case of retreatment, the costs are not covered under the pet insurance. The stem cell therapy is thus cost-prohibitive for a large number of pet owners, which highlights a major restraint to the market growth. Stem cell therapy is still in its developmental stage and a positive growth outcome for the market cannot be confirmed yet.

More:
COVID-19 Analysis | Canine Stem Cell Therapy Market by Trends, Dynamic Innovation in Technology and 2026 Forecasts - 3rd Watch News

Cortical Bone Derived Stem Cells Modulate Cardiac Fibroblast Response via miR-18a in the Heart After Injury – DocWire News

By Adult Stem Cells

The adult heart following injury such as a myocardial infarction forms a fibrotic scar associated with transformation of resident cardiac fibroblasts into myofibroblast, accelerating cardiac remodeling and dysfunction. Cell therapies provide a novel direction for the enhancement of cardiac structure and function but remain poorly described in terms of the effect on resident cardiac fibroblasts. We have shown cortical bone derived stem cells (CBSCs) exhibit an ability to repair the heart after myocardial injury together with reduced scar formation. Nevertheless, whether CBSCs possess ability to modulate resident fibroblast response after myocardial injury remains untested.

Objective:To determine the effect of secreted factors from CSBCs to attenuate myofibroblast formation in the heart after injury.

Methods and results:CBSCs were injected in mice after myocardial infarction which demonstrated reduced fibrosis as determined by Massons trichrome and Picro-Sirius red staining. In parallel, decreased expression of myofibroblast markers such as Acta2 was observed compared to PBS injected mice. To determine the effect of CBSCs on cardiac fibrosis, adult mouse cardiac fibroblasts were isolated from C57BL/6 mice, primed with CBSC pre-conditioned media for 12 h, and treated with 10ng TGF- for 48 h to mimic cardiac injury. Decreased expression of Acta2, periostin and CTGF was observed in adult cardiac fibroblasts cultured in CBSC medium compared to control cells. Additionally, analysis of myofibroblast markers such as vimentin and pSMAD/SMAD was also decreased compared to control cells. To determine the mechanism, we looked for enriched miRNA in CBSCs that can mediate anti fibrotic response after injury. Results showed significantly increased expression of miR-18a in CBSCs. The upregulation of miR-18a was also validated in adult fibroblasts treated with CBSCs compared to control cells. Adult fibroblasts treated with mimic for miR-18a followed by TGF- showed significant decrease in myofibroblast formation while miR-18a inhibitor completely inhibited the effect of CBSC medium.

Conclusion:CBSCs reduce fibroblast to myofibroblast transition and differentiation in adult cardiac fibroblasts via miR-18a-5p. This finding reveals a new avenue for cell therapies to target myocardial scar modulation and provides a resolution for the cardiac repair response after injury in the adult myocardium.

Visit link:
Cortical Bone Derived Stem Cells Modulate Cardiac Fibroblast Response via miR-18a in the Heart After Injury - DocWire News

Stem Cell Banking Market: In-depth Analysis of the Global Industry with Future Estimations till 2029 – Cole of Duty

By Stell Cell Research

Prophecy Market Insights Stem Cell Banking market research report provides a comprehensive, 360-degree analysis of the targeted market which helps stakeholders to identify the opportunities as well as challenges.

Initially, Stem Cell Banking report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Stem Cell Banking market analysis is provided for the international markets including development trends, competitive landscape analysis, geography, end-users, applications, market share, COVID-19 analysis, and forecast 2020-2029. It incorporates market evolution study, involving the current scenario, growth rate, and capacity inflation prospects, based on Porters Five Forces and DROT analyses.

Pandemic offer for our customers: Purchase this Report now by availing up to 40% Discount and free consultation. Limited period offer.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/281

As we all are well aware of pandemic and we dont know what lies ahead once this COVID-19 Pandemic crises are over. Our analysis involves the detailed study of the market taking into consideration the impact pandemic situation. We will be grateful if you get in touch with us so that we can understand your exact requirement and we can provide you with an exhaustive coverage of the impact of the current situation on the market. We also provide a customized report as per your requirement.

The executive summary provides the markets definition, application, overview, classifications, product specifications, manufacturing processes; raw materials, and cost structures.

Market Dynamics offers drivers, restraints, challenges, trends, and opportunities of the Stem Cell Banking market

Segment Level Analysis in terms of types, product, geography, demography, etc. along with market size forecast

Segmentation Overview:

The Stem Cell Banking research study comprises 100+ market data Tables, Graphs & Figures, Pie Chat to understand detailed analysis of the market. The predictions estimated in the market report have been resulted in using proven research techniques, methodologies, and assumptions. This Stem Cell Banking market report states the market overview, historical data along with size, growth, share, demand, and revenue of the global industry.

Regional and Country- level Analysis different geographical areas are studied deeply and an economical scenario has been offered to support new entrants, leading market players, and investors to regulate emerging economies. The top producers and consumers focus on production, product capacity, value, consumption, growth opportunity, and market share in these key regions, covering

Australia, New Zealand, Rest of Asia-Pacific

Stakeholders Benefit:

The comprehensive list of Key Market Players along with their market overview, product protocol, key highlights, key financial issues, SWOT analysis, and business strategies. The report dedicatedly offers helpful solutions for players to increase their clients on a global scale and expand their favour significantly over the forecast period. The report also serves strategic decision-making solutions for the clients.

Competitive landscape Analysis provides mergers and acquisitions, collaborations along with new product launches, heat map analysis, and market presence and specificity analysis.

Stem Cell BankingMarket Key Players:

Cryo-cell International, Inc., Stem Cyte, Inc., ViaCord, Inc., Cord Blood Registry , Inc., SmartCells, Inc., LifeCell International Pvt.Ltd, Cryoviva Biotech Pvt. Ltd., Cryo StemcelPrivate Limited, Reliance Life Sciences Private Limited, and Trascell Biolife Pvt. Ltd.

Request Discount @ https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/281

The study analyses the manufacturing and processing requirements, project funding, project cost, project economics, profit margins, predicted returns on investment, etc. With the tables and figures, the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Report Scope:

Europe

Asia Pacific

Latin America

Middle East & Africa

Some Important Questions Answered in the Market Report are:

Get In-depth TOC @ https://www.prophecymarketinsights.com/market_insight/Global-Stem-Cell-Banking-Market-281

Detailed analysis of the COVID-19 impact will be given in the report, as our analyst and research associates are working hard to understand the impact of COVID-19 disaster on many corporations, sectors and help our clients in taking excellent business decisions. We acknowledge everyone who is doing their part in this financial and healthcare crisis.

Pandemic offer for our customers: Purchase this Report now by availing up to 40% Discount and free consultation. Limited period offer.

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

VISIT MY BLOG:- https://prophecyconsumerelectronics.blogspot.com/

Original post:
Stem Cell Banking Market: In-depth Analysis of the Global Industry with Future Estimations till 2029 - Cole of Duty

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: What Effect is COVID 19 Bringing That Will Change the Industry Brainstorm Cell…

By Stell Cell Research

Autologous Stem Cell and Non-Stem Cell Based Therapies Market has witnessed continuous growth within the past few years and is projected to grow even more throughout the forecast period (2020 2027). The analysis presents a whole assessment of the market and contains Future trends, Current Growth Factors, attentive opinions, facts, historical information, and statistically supported and trade valid market information.

The report, titled Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market defines and briefs readers about its products, applications, and specifications. The research lists key companies operating in the global market and also highlights the key changing trends adopted by the companies to maintain their dominance. By using SWOT analysis and Porters five force analysis tools, the strengths, weaknesses, opportunities, and threats of key companies are all mentioned in the report. All leading players in this global market are profiled with details such as product types, business overview, sales, manufacturing base, competitors, applications, and specifications.

You Can Request A Demo Version of Report Before Buying (Higher Preference For Corporate Email ID User): https://www.worldwidemarketreports.com/sample/284124

Brainstorm Cell Therapeutics, Cytori, Dendreon Corporation, Fibrocell, Lion Biotechnologies, Caladrius Biosciences, Opexa Therapeutics, Orgenesis, Regenexx, Genzyme of the major organizations dominating the global market.(*Note: Other Players Can be Added per Request)

1. Industry outlookThis is where youll find the current state of the Autologous Stem Cell and Non-Stem Cell Based Therapies industry overall and where its headed. Relevant industry metrics like size, trends, life cycle, and projected growth included here. This report comes prepared with the data to back up your business idea. On a regional basis, the Global Autologous Stem Cell and Non-Stem Cell Based Therapies market has been segmented into Asia-Pacific, North America, Europe, Latin America, and the Middle East and Africa.

2. Target marketThis target market section of study includes the following:

User persona and characteristics: It includes demographics such as age, income, and location. It lets you know what their interests and buying habits are, as well as explain the best position to meet their needs.

Market size: How big is the potential Autologous Stem Cell and Non-Stem Cell Based Therapies market for your business? It brings to light the consumption in the Autologous Stem Cell and Non-Stem Cell Based Therapies industry by the type and application.

3. Competitive analysisDiscover your competitors. The report lets you know what youre up against, but it also lets you spot the competitions weaknesses. Are there customers that are underserved? What can you offer that similar businesses arent offering? The competitive analysis contains the following components:

Direct competitors: What other companies are offering similar products and services? Which companies are your true competitors?

Competitor strengths and weaknesses: What is your competition good at? Where do they fall behind? Get insights to spot opportunities to excel where others are falling short.

Barriers to entry: What are the potential pitfalls of entering the Autologous Stem Cell and Non-Stem Cell Based Therapies market? Whats the cost of entry? Is it prohibitively high, or easy to enter?

The window of opportunity:Does your entry into the Autologous Stem Cell and Non-Stem Cell Based Therapies industry rely on time-sensitive technology? Do you need to enter early to take advantage of an emerging market?

4. ProjectionsLikewise, We offered thoughtful, not hockey-stick forecasting.

Market share:We have given the consumption behavior of users. When you know how much can your future customers spend, then only youll understand how much of the Autologous Stem Cell and Non-Stem Cell Based Therapies industry you have a chance to grab, and here we came up with real stats and numbers.

Impact Analysis of COVID-19:The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into account the political, economic, social, and technological parameters.

Finally, It is one report that hasnt shied away from taking a critical look at the current status and future outlook for the consumption/sales of these products, by the end users and applications. Not forgetting the market share control and growth rate of the Autologous Stem Cell and Non-Stem Cell Based Therapies Industry, per application. Most noteworthy, this market analysis will help you find market blind spots.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends.

Contact Us:

Mr. ShahWorldwide Market ReportsSeattle, WA 98154,U.S.Email: [emailprotected]

Go here to read the rest:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market: What Effect is COVID 19 Bringing That Will Change the Industry Brainstorm Cell...

Citius Pharmaceuticals Brings on Myron S. Czuczman, MD as Chief Medical Officer (CMO) and Executive Vice President – BioSpace

By Stell Cell Research

CRANFORD, N.J., July 14, 2020 /PRNewswire/ --Citius Pharmaceuticals, Inc.. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that Myron S. Czuczman, M.D., has joined the company as Chief Medical Officer (CMO) and Executive Vice President. Dr. Czuczman was most recently Therapeutic Area Head, Vice President, Clinical Research and Development Global Lymphoma/CLL Program at Celgene Corporation. At Celgene, he was responsible for worldwide clinical development in Lymphoma/CLL and for the development of all compounds from Proof-of-Principle through registration globally.

Myron Holubiak, Citius CEO stated, "We are honored to have a colleague as qualified as Dr. Czuczman join the Citius team. He will be enormously helpful in furthering our development program for our planned iPSC-derived mesenchymal stem cell (iMSC) for the treatment of ARDS associated with CoVid-19. This, coupled with the advanced Phase 3 trials underway for Mino-Lok and preparing an IND for Mino-Wrap, add to the importance of bringing in an executive of Dr. Czuczman's expertise, experience, and caliber to the team."

Prior to his tenure at Celgene, Dr. Czuczman served as Chief, Lymphoma/Myeloma Service in the Department of Medicine and Head of the Lymphoma Translational Research Laboratory in the Immunology Department at Roswell Park Comprehensive Cancer Center in Buffalo, NY where he attained the title of tenured Professor of Medicine and Oncology prior to joining Celgene.

Dr. Czuczman received his M.D. from Pennsylvania State University of Medicine after graduating magna cum laude in Biochemistry from the University of Pittsburgh. He completed his Internal Medicine residency training at Weill Cornell North Shore University/MSKCC Program, followed by Medical Oncology/Hematology fellowship training at Memorial Sloan-Kettering Cancer Center in New York, NY.

Dr. Czuczman was a Founding Member and reviewer forthe National Comprehensive Cancer Network (NCCN) Lymphoma Guidelines compendium panel for nearly twenty years and he has greater than 180 peer-reviewed publications. He is a Diplomate in Internal Medicine, and is Board Certified in Medical Oncology and received numerous awards and accolades during his academic career.

About Citius Pharmaceuticals, Inc. Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visit http://www.citiuspharma.com.

About Mino-Lok Mino-Lok is an antibiotic lock solution being developed as an adjunctive therapy in patients with central line-associated bloodstream infections (CLABSIs) or catheter-related bloodstream infections (CRBSIs). CLABSIs/CRBSIs are very serious, especially in cancer patients receiving therapy through central venous catheters (CVCs) and in hemodialysis patients, for whom venous access presents a challenge. There are currently no approved therapies for salvaging infected CVCs.

About Citius iMSC Citius's planned mesenchymal stem cell therapy product is derived from a human induced pluripotent stem cell (iPSC) line generated using a proprietary mRNA-based (non-viral) reprogramming process. The iMSCs produced from this clonal technique are differentiated from adult donor-derived MSCs (bone marrow, placenta, umbilical cord, adipose tissue, or dental pulp) by providing genetic homogeneity. In in-vitro studies, iMSCs exhibit superior potency and high cell viability. The iMSCs secrete immunomodulatory proteins that may reduce or prevent pulmonary symptoms associated with acute respiratory distress syndrome (ARDS) in patients with COVID-19. The Citius iMSC is an allogeneic (unrelated donor) mesenchymal stem-cell product manufactured by expanding material from a master cell bank.

About Acute Respiratory Distress Syndrome (ARDS) ARDS is a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs. ARDS is a rapidly progressive disease that occurs in critically ill patients most notably now in those diagnosed with COVID-19. ARDS affects approximately 200,000 patients per year in the U.S., exclusive of the current COVID-19 pandemic, and has a 30% to 50% mortality rate. ARDS is sometimes initially diagnosed as pneumonia or pulmonary edema (fluid in the lungs from heart disease). Symptoms of ARDS include shortness of breath, rapid breathing and heart rate, chest pain (particularly while inhaling), and bluish skin coloration. Among those who survive ARDS, a decreased quality of life is relatively common.

Safe Harbor This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.

Factors that could cause actual results to differ materially from those currently anticipated are: our ability to attract, integrate, and retain key personnel; our need for substantial additional funds; the risk of successfully negotiating within the option period a license agreement with Novellus, Inc. for our planned Novecite therapy for ARDS; risks associated with conducting clinical trials and drug development; the estimated markets for our product candidates and the acceptance thereof by any market; risks related to our growth strategy; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; our dependence on third-party suppliers; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Andrew Scott Vice President, Corporate Development (O) 908-967-6677 x105 ascott@citiuspharma.com

View original content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-brings-on-myron-s-czuczman-md-as-chief-medical-officer-cmo-and-executive-vice-president-301092921.html

SOURCE Citius Pharmaceuticals, Inc.

See the article here:
Citius Pharmaceuticals Brings on Myron S. Czuczman, MD as Chief Medical Officer (CMO) and Executive Vice President - BioSpace

Advanced Therapy Medicinal Products Market Break Down By Leading Companies, Countries, Applications, Challenges, Opportunities And Forecast 2020-2026…

By Stem Cell Medicine

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Advanced Therapy Medicinal Products market.

Trusted Business Insights presents an updated and Latest Study on Advanced Therapy Medicinal Products Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Advanced Therapy Medicinal Products market during the forecast period (2019-2029). It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Advanced Therapy Medicinal Products Market Market Research and Industry Forecast Report, 2026 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Advanced Therapy Medicinal Products Market

The global advanced therapy medicinal products market size was valued at USD 3.14 billion in 2019 and is projected to expand at a CAGR of 17.4% during the forecast period. Recent advancements in biological therapies have resulted in a gradual shift toward personalized medicine from the conventional one-size fits all approach. The advanced therapy medicinal product (ATMP) landscape is one of the active spaces in this new trend. These products offer solutions for conditions with negligible therapeutic alternatives as well, which is one of the major growth drivers for the market. Although the regulation for ATMPs is currently in its nascent stage, it is a constantly developing area. The number of Investigational New Drug (IND) applications for these therapies continues to increase. Post-approval of Yescarta, Center for Biologics Evaluation and Research has received around 150 INDs in fiscal year 2018. According to the Alliance for Regenerative Medicine (ARM), more than 1,000 clinical trials were carried out for the ATMP designation to the products, by January 2019, globally.

With the approval of Luxturna, Yescarta, and Kymriah, this market has witnessed several acquisitions intended for market entry or expansion in the sector. For example, acquisition of Kite Pharma by Gilead Life Science, Juno Therapeutics by Celgene, and AveXis by Novartis are some of the notable acquisitions that took place in recent times. These acquisitions indicate the rising interest of major pharma companies in advanced therapy medicinal products. Although the companies have successfully secured product approvals in the past years, the high cost of therapies and challenges with respect to financial sustainability are anticipated to slowdown product adoption. Several products have been pulled off from the market as they were not considered financially viable for the developers as well as the payers. Moreover, some companies like Fibrocell have also witnessed the wind-down of their product operations. Despite the above-articulated challenges, this field is constantly expanding owing to the health benefits offered by these new classes of therapies, along with benefitting society and the healthcare system in context to healthcare outcome and resource availability. Considering the efficiency and clinical benefits of advanced therapy medicinal products, various stakeholders of the market are constantly designing strategies to overcome the existing challenges and spur advanced therapy medicinal products usage. Therapy Type Insights of Advanced Therapy Medicinal Products Market

Over the past few years, there has been a notable increase in the clinical development of advanced therapies, including gene therapies, cell therapies, and tissue engineering products. Several products have already secured approval in U.S., China, Europe, South Korea, Japan, Australia, Canada, India, and New Zealand. As a result, a substantial number of well-established as well as start-up pharma companies, universities, and hospitals are shifting their focus from conventional therapies to advanced therapies. Cell therapies held the largest revenue share of the advanced therapy medicinal products market in 2019. Increased funding from governments as well as private organizations to support cell therapy clinical trials, improving the legal framework for cell therapy manufacturing and implementation, and proven efficacy of products are some of the key drivers for the growth of the segment.

Based on cell types, stem cell therapies held the dominant revenue share in 2019 owing to the presence of a substantial number of approved therapies. The entry of new players such as Celularity, Rubius Therapeutics, Century Therapeutics, Fate Therapeutics, ViaCyte, Magenta Therapeutics, ReNeuron, Promethera Biosciences, Frequency Therapeutics, and Cellular Dynamics in the recent years reflects the expanding stem cells business operations. Currently, the number of approved gene therapy is limited, however, a substantial number of products is anticipated to receive regulatory approvals in the forthcoming years. Growing R&D activities in gene therapy trials have resulted in an increase in market activities by the key stakeholders operating in the ATMP market. For instance, in April 2019, Catalent announced to acquire Paragon Bioservices to expand its business footprint in the gene therapy arena.

Regional Insights of Advanced Therapy Medicinal Products Market

The presence of a substantial number of approved ATMPs for use in U.S. has contributed to the large revenue share of this region. The recent approval of products like Kymriah, Yescarta, and Zolgensma has propelled the investment in the U.S. ATMP market. Furthermore, the U.S. FDA has announced that it has over 800 active Investigational New Drug applications on file by 2020 and the agency showed interest to receive more than 200 applications per year. In 2017, an estimated 391 gene therapy companies were operating in the U.S. market. In September 2019, around a hundred more companies including Big Pharma companies had entered the market. These factors are anticipated to accelerate the North America market at a lucrative CAGR in the forthcoming years. Europe is the second-largest pharmaceutical market globally, with Western Europe accounting for the large proportion of drug revenue. In the forthcoming years, cell therapy developers are anticipated to account for a major share of Europes drug revenues. In addition, the presence of a substantial number of academic institutes engaged in conducting early-stage cell therapy research is anticipated to boost the regional revenue growth. Furthermore, global companies are expanding their cell therapy manufacturing capabilities across Europe, thereby driving the regional market growth.

Market Share Insights of Advanced Therapy Medicinal Products Market

Currently, this market is a very active space. Recent approvals of ATMPs have prompted an unprecedented expansion in this area. Conventional drug makers are striving to gain a competitive advantage, considering ATMP as a lucrative source of revenue in the future healthcare systems. Companies are investing enormously in clinical trials of ATMP post the success of approved products. Some major players are Spark Therapeutics, Inc.; Bluebird Bio, Inc.; Novartis AG; UniQure N.V.; Celgene Corporation; Gilead Lifesciences, Inc.; Kolon TissueGene, Inc.; JCR Pharmaceuticals Co., Ltd.; MEDIPOST; Vericel Corporation; PHARMICELL Co., Ltd; and Organogenesis Inc. The companies are adopting various operating models to accelerate the product manufacturing process. While some companies undertake in-house production of therapies, a substantial number of players are preferring third-party service providers, including Contract Manufacturing Organizations (CMOs). The gene therapy contract development market space is driven by the surging demand that stems from the expansion of drug development pipeline and the rise in the number of start-ups that embrace human-testing but lack production capacities. On the other hand, several companies have marked their presence in the space by acquiring small and emerging CAR T-cell therapy developers.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Advanced Therapy Medicinal Products Market Research Report This report forecasts revenue growth at global, regional, and country levels and provides an analysis of latest industry trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, this market research report has segmented the global advanced therapy medicinal products market report on the basis of therapy type and region:

Therapy Type Outlook (Revenue, USD Million, 2019 2030)

Cell Therapy

Stem Cell Therapy

Non-stem Cell Therapy

CAR-T Therapy

Gene Therapy

Tissue Engineered Product

Quick Read Table of Contents of this Report @ Advanced Therapy Medicinal Products Market Market Research and Industry Forecast Report, 2026 (Includes Business Impact of COVID-19)

Trusted Business Insights Shelly Arnold Media & Marketing Executive Email Me For Any Clarifications Connect on LinkedIn Click to follow Trusted Business Insights LinkedIn for Market Data and Updates. US: +1 646 568 9797 UK: +44 330 808 0580

Continued here:
Advanced Therapy Medicinal Products Market Break Down By Leading Companies, Countries, Applications, Challenges, Opportunities And Forecast 2020-2026...

Stem cell breakthrough: Japanese scientists discover way …

By Embryonic Stem Cells

A new way of creating stem cells that is cheaper, faster and more efficient than before could transform the ability of scientists to develop "personalised medicine" where a patients own healthy skin or blood cells can be used to repair damaged tissues, such as heart disease or brain injury.

Japanese scientists announced today that they had created stem cells which are essential for bodily repair by simply bathing blood cells in a weakly acidic solution for half an hour, triggering a remarkable reversion to the cells original embryonic state.

Researchers in Britain said they were astonished by the ease with which their colleagues in Japan had created embryonic-like stem cells with the ability to develop into any of the dozens of highly specialised cells of the body, ranging from cardiac-muscle cells to the nerve cells of the brain and spinal cord.

It opens up the prospect of doctors taking small samples of skin or blood from a patient and using the tissue to create stem cells that could be injected back into the same patient as part of a "self-repair" kit to mend damaged organs without the risk of tissue rejection.

The stunning breakthrough was even more striking in that it was made by a young Japanese researcher called Haruko Obokata of the Riken Centre for Developmental Biology in Kobe who could not at first believe her own results and when she did finally believe them she found it just as difficult to persuade her colleagues that they were not a mistake

"I was really surprised the first time I saw [the stem cells] Everyone said it was an artifact there were some really hard days," Dr Obokata said. Although the research was carried out on mouse cells, it should also work with human cells, she said.

"Its exciting to think of the new possibilities this finding provides us not only in areas like regenerative medicine but perhaps in the study of cell senescence [ageing] and cancer as well. As regards human cells, that project is underway," she added.

Previously, stem cells with the ability to develop into any specialised tissue a phenomenon called pluripotency could only be created either by extracting them from early embryos or by genetically manipulating adult cells to create so-called induced pluripotent stem (iPS) cells.

However, creating and destroying human embryos raises ethical questions for many people and is fraught with practical difficulties, while using iPS cells in human medicine is raises safety concerns about using genetically modified cells. Both techniques are also costly, inefficient and time-consuming.

The new approach, based simply on bathing blood or skin cells in a weak solution of citric acid for 30 minutes, is not only much quicker and cheaper than the previous two techniques, it is also so simple that it could be carried out in labs without any particularly specialised knowledge or equipment.

No hype, just the advice and analysis you need

To test that the cells were truly pluripotent, Dr Obokata and her colleagues labelled them with a green fluorescent gene, injected them into early mouse embryos and found that they colonised every tissue of the developing foetus, even its umbilical cord which does not happen with classical embryonic stem cells and iPS cells.

The Japanese scientists, who collaborated with Charles Vacanti of Harvard Medical School in Boston, said that in addition to blood cells, they have also created stem cells from the brain, skin, muscle, fat, bone-marrow, lung and liver tissues of newborn mice. They have called the technique stimulus-triggered acquisition of pluripotency (STAP) and believe there may be other ways of shocking adult cells to revert to their embryonic condition other than bathing them in a weak acid solution.

Professor Vacanti said: "It may not be necessary to create an embryo to acquire embryonic stem cells. Our research findings demonstrate that creation of an autologous pluripotent stem cell a stem cell from an individual that has the potential to be used for therapeutic purpose without an embryo, is possible."

Scientists in Britain said the findings were extraordinary and unexpected. The results rewrite the rulebook on how the specialised cells of the mammalian body are meant to behave once they have travelled down what was thought to be the one-way street of cell differentiation, they said.

"Obakatas approach in the mouse is the most simple, lowest cost and quickest method to generate pluripotent cells from mature cells," said Professor Chris Mason, an expert in regenerative medicine at University College London.

"If it works in man, this could be the game changer that ultimately makes a wide range of cell therapies available using the patients own cells as starting material the age of personalised medicine would have finally arrived," Professor Mason said.

"Who would have thought that to reprogram adult cells to an embryonic stem cell-like (pluripotent) state just required a small amount of acid for less than half an hour? An incredible discovery," he added.

Professor Robin Lovell-Badge, head of stem cell biology at the MRCs National Institute for Medical Research in north London, said: "It is going to be a while before the nature of these cells are understood, and whether they might prove to be useful for developing therapies, but the really intriguing thing to discover will be the mechanism underlying how a low pH [acidic] shock triggers reprogramming. And why it does not happen when we eat lemon or vinegar or drink cola?"

The rest is here:
Stem cell breakthrough: Japanese scientists discover way ...

Types of Stem Cells

By Embryonic Stem Cells

Totipotent SCs:

These cells have total potentiality to form a complete full organism. Totipotent SCs are well known for their capability of differentiating into all cell types and lineages that can form different types of tissues and organs. Totipotent SCs have unlimited capability, and in the early stages of embryonic development. They can differentiate to extra embryonic membranes and tissues, the embryo, the postembryonic tissues and final organs.

More specialized cells in generating different types of tissues and organs. These types of cells can differentiate into any cells type but are incapable of producing a whole organism. Pluripotent SCs can give rise to types of cells that develop from the three germ layers (ectoderm, mesoderm, and endoderm). Induced Pluripotent stem cells (iPSCs) are a type of Pluripotent stem cells generated by the genetic introduction of 4 genes encoding for transcription factors that can induce the conversion of adult cells into Pluripotent stem cells.

These SCs are more specialized cells that are usually found in different organs of the human body. They are capable of forming cells from more than one germ layer and differentiating to different cell types within the same organ or tissue. Pluripotent and multipotent SCs share common characteristics and can be easily confused with one another. Accordingly, the classification of either type depends solely on the differentiation potential of each type of cell. Furthermore, the differentiation potential of multipotent SCs is not easily understood for several reasons. These include the fact that their physiological sites of survival referred to as stem cell niches usually differ from one site to another. In general, individual multipotent stem cells, that are part of a homogenous population of SCs, are usually committed to forming one cell lineage, compared to pluripotent SCs that have the potential to form more than one cell lineage.

These cells are commonly found in specific organs and tissues of adult organisms and are limited to differentiating to one cell type only, depending on a complex structure of intrinsic and extrinsic factors. These SCs are responsible for the steady state of self-renewal through constant regeneration and repair of that organ.

There are two main sources of stem cells:

Pluripotent cells that exist in the early stages of embryonic development, specifically in the inner mass of blastocysts, and go on to form all the cells of the adult body. These cells no longer exist after five days of development.

SCs that can be found in almost all body tissues including blood, brain, liver, intestine, or skin. They are more tissue specific cells committed to become a cell from their own tissue of origin, but cannot go to form all tissues of the body.

Based on the differentiation potentiality of SCs, they can be categorized into hematopoietic stem cells (HSCs) and non-hematopoietic stem cells (NHSCs). HSCs are cells that give rise to blood cell lineages and are capable of differentiating to white blood cells (WBCs), red blood cells (RBCs), and platelets. NHSCs are cells that give rise to tissues and organs other than blood.

Link:
Types of Stem Cells

→←